Entrada Therapeutics appoints Dr. Bernhardt Zeiher to Board of Directors

Entrada Therapeutics, Inc.

Board expanded from 7 to 8; Dr. Zeiher appointed as Class II director and to Nominating and Corporate Governance Committee.
Dr. Zeiher most recently served as Chief Medical Officer at Astellas Pharma; brings clinical and regulatory expertise.
Received initial option for 32,000 shares vesting over 3 years; annual director fee of $40,000 plus committee fee.
Entrada's lead programs include Duchenne muscular dystrophy and myotonic dystrophy type 1.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Bernhardt Zeiher

Director

TRDA · Entrada Therapeutics, Inc.

Effective: 2023-04-04
Filed: April 4, 2023, 7:59 PM ET

Effective as of April 4, 2023, the Board of Directors (the “Board”) of Entrada Therapeutics, Inc. (the “Company”) expanded the size of the Board from seven to eight directors and appointed Bernhardt Zeiher, M.D. to the Board as a Class II director, to serve until the annual meeting of stockholders held in 2023 or until his successor is duly elected and qualified.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Bernhardt Zeiher was appointed as Director at Entrada Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

Effective as of April 4, 2023, the Board of Directors (the “Board”) of Entrada Therapeutics, Inc. (the “Company”) expanded the size of the Board from seven to eight directors and appointed Bernhardt Zeiher, M.D. to the Board as a Class II director, to serve until the annual meeting of stockholders held in 2023 or until his successor is duly elected and qualified.

View on SEC.gov

Entrada Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001689375-23-000023

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.